JP2022543056A5 - - Google Patents

Info

Publication number
JP2022543056A5
JP2022543056A5 JP2022506461A JP2022506461A JP2022543056A5 JP 2022543056 A5 JP2022543056 A5 JP 2022543056A5 JP 2022506461 A JP2022506461 A JP 2022506461A JP 2022506461 A JP2022506461 A JP 2022506461A JP 2022543056 A5 JP2022543056 A5 JP 2022543056A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
construct
myr
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506461A
Other languages
English (en)
Japanese (ja)
Other versions
JP7636812B2 (ja
JP2022543056A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043813 external-priority patent/WO2021021774A1/en
Publication of JP2022543056A publication Critical patent/JP2022543056A/ja
Publication of JP2022543056A5 publication Critical patent/JP2022543056A5/ja
Application granted granted Critical
Publication of JP7636812B2 publication Critical patent/JP7636812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506461A 2019-07-29 2020-07-28 創傷治癒を促進するための組成物および方法 Active JP7636812B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879717P 2019-07-29 2019-07-29
US62/879,717 2019-07-29
PCT/US2020/043813 WO2021021774A1 (en) 2019-07-29 2020-07-28 Composition and method for promoting wound healing

Publications (3)

Publication Number Publication Date
JP2022543056A JP2022543056A (ja) 2022-10-07
JP2022543056A5 true JP2022543056A5 (enExample) 2023-07-31
JP7636812B2 JP7636812B2 (ja) 2025-02-27

Family

ID=72047146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506461A Active JP7636812B2 (ja) 2019-07-29 2020-07-28 創傷治癒を促進するための組成物および方法

Country Status (7)

Country Link
US (1) US20220265759A1 (enExample)
EP (1) EP4003393A1 (enExample)
JP (1) JP7636812B2 (enExample)
KR (1) KR20220042200A (enExample)
CA (1) CA3148980A1 (enExample)
MX (1) MX2022001020A (enExample)
WO (1) WO2021021774A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116121305B (zh) * 2023-01-03 2024-11-22 广州医科大学附属第五医院 间充质干细胞在糖尿病相关疾病中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
JPS6229997A (ja) 1985-04-08 1987-02-07 Sankyo Co Ltd Ｃ末端にプロリンアミドを有するペプチドの製法
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5580751A (en) 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
WO1993002697A1 (en) 1991-08-08 1993-02-18 Amylin Pharmaceuticals, Inc. Production of peptide amides
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US5709878A (en) 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
AUPP697698A0 (en) * 1998-11-06 1998-12-03 St. Vincent's Institute Of Medical Research Regulation of enzyme activity
EP1553973A4 (en) * 2002-08-16 2006-03-01 Schering Ag MUTANTS OF ENOS USEFUL FOR GENE THERAPY
ES2637956T3 (es) 2003-01-24 2017-10-18 Stiefel Research Australia Pty Ltd Espuma farmacéutica
AU2006259408A1 (en) 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
AU2007293475A1 (en) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009012435A1 (en) * 2007-07-19 2009-01-22 The Trustees Of The University Of Pennsylvania Conformational entropy in molecular recognition
WO2011062155A1 (ja) * 2009-11-19 2011-05-26 タカラバイオ株式会社 変異型Ｇａｇタンパク質をコードする核酸

Similar Documents

Publication Publication Date Title
US5482706A (en) Transmucosal therapeutic composition
Siegler et al. Prevention of postoperative adhesions in rabbits with ibuprofen, a nonsteroidal anti-inflammatory agent
JP2015512876A5 (enExample)
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
JP2022512478A5 (enExample)
JP2002523518A5 (enExample)
JP2002527401A5 (enExample)
CA2332817A1 (en) Il-6 antagonist peptides
JP2022515720A5 (enExample)
JP7766602B2 (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の肺疾患の治療的使用
JP2022506716A5 (enExample)
JP2022543056A5 (enExample)
GB2630492A (en) Episynchrons for precision medicine
WO2003048192A1 (en) Novel peptides and medicinal uses thereof
JP2008526935A5 (enExample)
JPH0211598A (ja) アミド化タウリンまたはグリシンの酸付加塩、それらの製法および用途
CN102205114B (zh) 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用
WO2018067460A1 (en) Erfe fusion polypeptides compositions and methods of use
JPH06287146A (ja) 皮膚外用剤
US20230181697A1 (en) Use of Surfactant Protein D to Treat Viral Infections
JP2002539829A5 (enExample)
JPH09500088A (ja) 創傷治癒用組成物
JP2021531246A5 (enExample)
JP2024516605A5 (enExample)
EP1781324A2 (en) Pharmaceutically active insulin receptor-modulating molecules